跳至主要内容
临床试验/ACTRN12623000152628
ACTRN12623000152628尚未招募未知

Acceptability, feasibility and impacts of remote symptom monitoring and automated treatment plans in children with Cystic Fibrosis (CF) on highly effective modulators: a pilot randomised controlled trial.

Royal Children's Hospital0 个研究点目标入组 30 人开始时间: 2023年2月16日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Diagnosis
盲法
Open (masking not used)

入排标准

年龄范围
5 Years 至 19 Years(—)
性别
All

入选标准

  • Diagnosis of Cystic Fibrosis
  • -On a highly effective modulator (either ivacaftor or elexacaftor–tezacaftor–ivacaftor for a minimum of 2 weeks)
  • -Clinically stable without antibiotic treatment for a pulmonary exacerbation in 2 weeks prior to consent
  • -Attending RCH CF clinic
  • -Able to complete home spirometry (standard of care for all children with CF >5 years at RCH CF clinic)
  • -Sufficient English to complete a survey
  • -Access to a smart phone to access remote symptom monitoring surveys

排除标准

  • -Participants not signed up or not willing to sign up to the RCH Portal (note that 80% of RCH CF patients are already signed up to the portal)
  • -Participants who do not have access to a smartphone or computer on a daily basis
  • -Participants who do not have access to a home spirometer for lung function purposes
  • -Participants will be excluded from the study for technological access reasons such as lack of access to the RCH Portal and IT equipment as this is the basis of the intervention.

研究者

相似试验

Acceptability, feasibility and impacts of remote... | 临床试验